Please login to the form below

Not currently logged in
Email:
Password:

Akari Therapeutics strengthens board

Hires Michael Grissinger and Dr Peter Feldschreiber

Mike GrissingerBiopharmaceutical company Akari Therapeutics has bolstered its board of directors with the addition of Michael Grissinger and Dr Peter Feldschreiber.

Grissinger (pictured right) has spent 22 years at Johnson & Johnson, holding positions of vice president and head of worldwide pharmaceutical licencing, as well as vice president and head of worldwide pharmaceutical corporate development and M&A.

His expertise has seen him led transactions across a broad span of deal-types, geographies, and therapeutic disease areas and he brings experience in business and corporate development, finance, marketing and strategic planning to Akari.

Alongside Grissinger, Dr Peter Feldschreiber also joins the board bringing 20 years’ experience in the pharmaceutical industry.

He has held appointments as senior medical assessor and special litigation coordinator to the healthcare products regulatory agency.

Ray Prudo, executive chairman of Akari Therapeutics, said: “We are pleased to strengthen our board with two individuals that bring such a range and depth of healthcare industry experience.

“As Akari continues its mission to develop and commercialise treatments for orphan autoimmune and inflammatory disease, we look forward to benefitting from Michael’s expertise as a successful business and corporate development leader and Peter’s insight as a medical doctor with experience both in the pharmaceutical industry and the legal and regulatory aspects of healthcare.”

31st January 2018

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Syneos Health®

Syneos Health® (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. The Company, including a Contract Research Organization (CRO) and...

Latest intelligence

What does the future hold for clinical trial recruitment?
The past couple of years have raised several aspects of healthcare in the public’s consciousness – and one of the leading ones has been the role of clinical trials in...
When is an agency not an agency?
The PR Week UK Top 150 Consultancies prompts anticipation and curiosity. But can a virtual collective of freelancers fairly be compared and ranked against conventional agencies?...
Why big pharma needs to be braver
The last few years have seen the pharmaceutical industry undergo a rapid metamorphosis in the face of unprecedented change, but communications are one area that still needs an injection of...